Please assess the completion status of the following clinical trial:

Trial Title: USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria~1. Not younger than 18 years of either sex~2. Health personnel from the Dr. Alberto Eurnekian Interzonal University Hospital~3. No COVID-19 related symptoms~4. Able to understand and give written informed consent~Exclusion criteria~1. Known hypersensitivity or allergy to any component of the product under evaluation~2. Age under 18 years~3. Use of immunosuppressants (including systemic corticosteroids) in the past 30 days.~4. Pregnant or nursing.~5. Patients with other acute infectious diseases.~6. Patients with autoimmune disease and / or decompensated chronic diseases.~7. Unable to fulfill the administrative tasks proposed by the study.~8. Infection with SARSCoV-2 confirmed by PCR or rapid test authorized by ANMAT.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- IVER+ (Type: None): Adults, both genders, no age limit. They will be provided with topical medication, to be used 5 times a day. They will follow standard prophylactic measures and use PPE as suggested by OMS.
- IVER- (Type: None): Adults, both genders, no age limit They will follow standard prophylactic measures and use PPE suggestions, only.

Based on this trial design, predict the completion outcome and termination type (if applicable).